Rallybio Newsroom
March 2, 2021 | Press Releases
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
NEW HAVEN, Conn., March 02, 2021 – Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the details of two previously undisclosed pipeline programs. RLYB212 is a novel monoclonal antibody to human platelet antigen (HPA)-1a in preclinical development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disorder that can cause uncontrolled bleeding in fetuses and newborns. RLYB116 is a small protein inhibitor of complement factor 5 (C5) suitable for subcutaneous administration in preclinical development for the treatment of patients with severe and rare diseases of complement dysregulation. Rallybio plans to submit clinical trial applications for both RLYB212 and RLYB116 in the second half of 2021.
February 24, 2021 | News
COWEN Investor Conference
Rallybio will be participating in one-on-one meetings during the upcoming Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021.
February 16, 2021 | News
SVB Leerink 10th Annual Global Healthcare Conference
Rallybio will be participating in one-on-one meetings during the upcoming SVB Leerink 10th Annual Global Healthcare Conference, a virtual event taking place February 22-26, 2021.
January 21, 2021 | Press Releases
Steven Tuch Joins Rallybio to Lead Corporate Development
NEW HAVEN, CT, January 21, 2021 – Rallybio LLC, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Steven Tuch to lead the Company’s corporate development function. In this role, Mr. Tuch, a seasoned healthcare business professional, will have responsibility for Rallybio’s financing and capital allocation strategies and will also partner with the Business Development team to review and assess opportunities for transformative corporate deals, partnerships, and acquisitions.
November 24, 2020 | Press Releases
Rallybio to Present at the 3rd Annual Evercore ISI HealthCONx Conference
NEW HAVEN, Conn., November 24, 2020 – Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Chief Executive Officer, Jeff Fryer, Chief Financial Officer and Steve Uden, Chief Operating Officer, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 4:20 p.m. Eastern Time.
November 10, 2020 | Press Releases
Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study
NEW HAVEN, Conn., November 10, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that dosing has commenced in a Phase 1/2 study evaluating RLYB211, a plasma-derived hyperimmune globulin, in healthy male participants. RLYB211 is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disorder that can cause uncontrolled bleeding in fetuses and newborns.
November 5, 2020 | Press Releases
Rallybio to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
NEW HAVEN, Conn., November 5, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Steve Uden, M.D., Co-Founder and Chief Operating Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Tuesday, November 10, 2020 at 5:00 p.m. Eastern Time.
November 2, 2020 | Press Releases
Rallybio Appoints Paula Soteropoulos to Board of Directors
NEW HAVEN, Conn., November 2, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that it has appointed Paula Soteropoulos to its Board of Directors. Ms. Soteropoulos is an accomplished biopharmaceutical industry leader with more than 30 years of rare disease experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation and company building.
September 11, 2020 | Press Releases
Rallybio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
NEW HAVEN, Conn., September 11, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Co-Founder and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 4:15 p.m. Eastern Time.
September 3, 2020 | Press Releases
Rallybio Appoints Helen M. Boudreau to Board of Directors
NEW HAVEN, Conn., September 3, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that it has appointed Helen M. Boudreau, former Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, to its Board of Directors. Ms. Boudreau will also serve as Chair of the Audit Committee.
June 19, 2020 | Press Releases
Jackie Schumacher Joins Rallybio to Lead Global Regulatory Affairs
NEW HAVEN, Conn., June 19, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Jackie Schumacher to lead Global Regulatory Affairs. In this role, Ms. Schumacher will have responsibility for Rallybio’s global regulatory strategy and operations across the portfolio, including the Company’s lead product candidate, RLYB211, which is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
June 3, 2020 | News
Rallybio Named Innovator of the Month by Senator Chris Murphy (D-Conn)
Rallybio is honored to be named Senator Murphy’s Innovator of the Month, highlighting our commitment to developing innovative, life-transforming medicines right here in Connecticut. We have been working diligently to advance our pipeline and expand our portfolio of transformative therapies for the treatment of patients suffering from rare and ultra-rare diseases. We are thrilled to be recognized for our accomplishments along with other emerging companies in the state, and look forward to continued growth for both Rallybio and the biopharmaceutical industry as a whole in Connecticut.
May 28, 2020 | Press Releases
Rallybio Further Broadens Drug Development Capabilities with Addition of Róisín Armstrong, PhD
NEW HAVEN, Conn., May 28, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Róisín Armstrong, PhD. Dr. Armstrong, a seasoned drug developer, will head the development of the Company’s lead program, RLYB211. RLYB211, a plasma-derived hyperimmune globulin, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
May 19, 2020 | Press Releases
Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020
— Financing Led by Pivotal bioVenture Partners
May 5, 2020 | Press Releases
Rachael Alford, PhD Joins Rallybio to Lead CMC Operations
NEW HAVEN, Conn., May 5, 2020 – Rallybio LLC, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Rachael Alford, PhD to lead the Company’s Chemistry, Manufacturing and Controls (CMC) operations. In this role, Dr. Alford will have responsibility for overseeing the process development, analytical and formulation development, and manufacturing and supply chain of Rallybio’s product candidates.
April 7, 2020 | Press Releases
Michael Greco, JD Joins Rallybio to Head Legal Operations
NEW HAVEN, Conn., April 7, 2020 – Rallybio LLC, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Michael Greco, JD to lead the Company’s legal function. In this role, Mr. Greco will have responsibility for Rallybio’s legal, intellectual property, compliance and governance activities.
October 31, 2019 | Press Releases
Rallybio Expands Leadership Team and Strengthens Drug Acquisition Capabilities
FARMINGTON, Conn., October 31, 2019 – Rallybio LLC, a development-stage biotechnology company, today announced that it has further expanded its drug acquisition and development capabilities with the addition of Amanda Hayward, PhD and Lisa Sinclair, to the Rallybio team. Specifically, Dr. Hayward will focus on further building Rallybio’s portfolio and Ms. Sinclair will be focused on new product commercial planning including diagnostic and patient access approaches to support the portfolio. These leadership appointments further advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. Amanda Hayward, PhD
September 12, 2019 | Press Releases
Rallybio Broadens Team Capabilities with Addition of Douglas Sheridan, PhD
FARMINGTON, Conn., September 12, 2019 – Rallybio LLC, a development-stage biotechnology company, today announced that it has broadened its drug development capabilities with the addition of Douglas Sheridan, PhD. Dr. Sheridan, a seasoned R&D leader, has significant drug development experience, including discovery, strategic planning and clinical program management. He will help advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders.
August 8, 2019 | Press Releases
Rallybio Expands Drug Development Team with Addition of Ann Willauer, PMP
Rallybio Expands Drug Development Team with Addition of Ann Willauer, PMP
January 3, 2019 | Press Releases
Rallybio Further Strengthens Leadership Team with Addition of Steven Ryder
R&D Executive with Proven Track Record in the Biopharmaceutical Industry
October 2, 2018 | Press Releases
FierceBiotech Names Rallybio as One of its “Fierce 15” Biotech Companies of 2018
Award recognizes Rallybio as being among “the most promising private biotech startups”
August 7, 2018 | Press Releases
Rallybio Further Expands Drug Acquisition and Development Capabilities
Rallybio Welcomes Laura Ekas, PhD and Eric Watsky, MD, Further Expanding Rallybio’s Drug Acquisition and Development Capabilities
July 10, 2018 | Press Releases
Rallybio Expands Drug Acquisition and Development Capabilities
Rallybio Expands Drug Acquisition and Development Capabilities with Addition of Veteran Industry Executives Zubin Bhagwagar, MD, PhD and Haren Vasavada, PhD, join Rallybio to identify and advance early-stage assets into clinical development
June 2, 2018 | News
BIO 2018
The Rallybio team is excited about the BIO International Convention that kicks off on Monday in Boston. Over 17,000 biotech colleagues from 74 countries will converge on the Boston Convention & Exhibition Center and the Rallybio team has a full schedule of dozens of partnering meetings. We are going to be based out of the Connecticut sponsored booth so if you’re going to be at the conference, swing by the booth and say hello.
April 24, 2018 | Press Releases
Rallybio Completes $37.0M Series A Financing
FARMINGTON, Conn., April 25, 2018 – Rallybio, LLC, a biotechnology company established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders, today announced that it has secured $37.0 million in Series A funding. 5AM Ventures, Canaan Partners, and New Leaf Venture Partners led the financing, with additional public-sector participation from Connecticut Innovations.
March 7, 2018 | News
Connecticut Bioscience Advocacy 2018
Rallybio will be attending Connecticut Bioscience Advocacy 2018 on Thursday, March 15th, at the Capitol in Hartford. The conference is being hosted by BioCT and will focus on the importance of bioscience to our state’s economy and future biosciences crossroads.
February 22, 2018 | News
CT Rare Disease Day
The Rallybio team will be attending the 2018 Connecticut Rare Disease Day Advocacy Event in Hartford on Wednesday, February 28th.
January 5, 2018 | News
Rallybio Incorporated!
It’s official! After months of planning, Martin, Steve and I have officially founded Rallybio, LLC. It is our hope that we are able to create a world-leading biotechnology organization that transforms the lives of patients with devastating diseases and built around people with an outstanding track record in pharmaceutical research and development.
December 11, 2017 | News
Lab Opened!
The Fryers, Mackays, and the Udens celebrated the opening of the Rallybio laboratory at the UConn Technology and Incubator Program facility in Farmington, CT. https://tip.uconn.edu/ We so thankful to all of the people and organizations who have helped us so far as we open our doors for the future.